[go: up one dir, main page]

CO2018012002A2 - Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor - Google Patents

Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor

Info

Publication number
CO2018012002A2
CO2018012002A2 CONC2018/0012002A CO2018012002A CO2018012002A2 CO 2018012002 A2 CO2018012002 A2 CO 2018012002A2 CO 2018012002 A CO2018012002 A CO 2018012002A CO 2018012002 A2 CO2018012002 A2 CO 2018012002A2
Authority
CO
Colombia
Prior art keywords
pain
compounds
subunit
voltage
tetrahydropyrimidodiazepine
Prior art date
Application number
CONC2018/0012002A
Other languages
English (en)
Inventor
Rosales Carmen Almansa
Cordobés Félix Cuevas
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of CO2018012002A2 publication Critical patent/CO2018012002A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos nuevos de fórmula general (I) que muestran una gran afinidad y actividad respecto a la subunidad α2δ de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad α2δ-1 de los canales de calcio dependientes de voltaje, o una actividad dual respecto a la subunidad α2δ de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad α2δ-1 de los canales de calcio dependientes de voltaje, y el transportador de noradrenalina (NET). La invención también se refiere al proceso para la preparación de dichos compuestos, así como también a las composiciones que los comprenden y su uso como medicamentos.
CONC2018/0012002A 2016-05-06 2018-11-29 Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor CO2018012002A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382199 2016-05-06
PCT/EP2017/060780 WO2017191304A1 (en) 2016-05-06 2017-05-05 Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions

Publications (1)

Publication Number Publication Date
CO2018012002A2 true CO2018012002A2 (es) 2019-04-30

Family

ID=56024209

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012002A CO2018012002A2 (es) 2016-05-06 2018-11-29 Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor

Country Status (33)

Country Link
US (1) US10590140B2 (es)
EP (1) EP3452475B1 (es)
JP (1) JP6926197B2 (es)
KR (1) KR20190024876A (es)
CN (1) CN109526220B (es)
AR (1) AR108387A1 (es)
AU (1) AU2017260305B2 (es)
BR (1) BR112018072755A2 (es)
CA (1) CA3023379A1 (es)
CO (1) CO2018012002A2 (es)
CY (1) CY1123231T1 (es)
DK (1) DK3452475T3 (es)
ES (1) ES2789676T3 (es)
HR (1) HRP20200668T1 (es)
HU (1) HUE051829T2 (es)
IL (1) IL262825A (es)
LT (1) LT3452475T (es)
ME (1) ME03726B (es)
MX (1) MX383520B (es)
MY (1) MY196791A (es)
PH (1) PH12018502337A1 (es)
PL (1) PL3452475T3 (es)
PT (1) PT3452475T (es)
RS (1) RS60528B1 (es)
RU (1) RU2018141084A (es)
SG (1) SG11201809799WA (es)
SI (1) SI3452475T1 (es)
SM (1) SMT202000365T1 (es)
TN (1) TN2018000372A1 (es)
TW (1) TWI736619B (es)
UA (1) UA123789C2 (es)
WO (1) WO2017191304A1 (es)
ZA (1) ZA201807653B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076904A1 (en) * 2017-10-16 2019-04-25 Esteve Pharmaceuticals, S.A. PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN
BR112020008371A2 (pt) * 2017-10-27 2020-11-03 Esteve Pharmaceuticals, S.A. novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
WO2019110137A1 (en) * 2017-12-04 2019-06-13 Esteve Pharmaceuticals, S.A. O-phenoxy and o-benzyloxypropylamino derivatives having activity against pain
WO2019115008A1 (en) * 2017-12-12 2019-06-20 Esteve Pharmaceuticals, S.A. Dialkylaminoarylpiperidinyl-o-phenoxy and o-benzyloxypropylamino derivatives having multimodal activity against pain
WO2019149919A1 (en) * 2018-02-05 2019-08-08 Esteve Pharmaceuticals, S.A. Aminopropoxypiperidinylamido derivatives having multimodal activity against pain
WO2020089263A1 (en) * 2018-10-31 2020-05-07 Esteve Pharmaceuticals, S.A. Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物
EP3873902A1 (en) * 2018-11-02 2021-09-08 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions
CN113661163B (zh) * 2019-02-28 2025-08-26 国立大学法人大阪大学 用于修饰蛋白质和/或肽的分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292241B2 (en) * 2000-09-27 2005-12-22 Ajinomoto Co., Inc. Benzodiazepine derivative
CA2488566A1 (en) 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2351367T3 (es) * 2006-02-14 2011-02-03 Vertex Pharmaceuticals Incorporated Dihidrodiazepinas útiles como inhibidores de proteína quinasas.
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)

Also Published As

Publication number Publication date
CA3023379A1 (en) 2017-11-09
CY1123231T1 (el) 2021-10-29
ME03726B (me) 2021-01-20
AU2017260305B2 (en) 2021-04-01
RU2018141084A3 (es) 2020-06-11
JP6926197B2 (ja) 2021-08-25
CN109526220A (zh) 2019-03-26
TWI736619B (zh) 2021-08-21
MX383520B (es) 2025-03-14
BR112018072755A2 (pt) 2019-02-19
SG11201809799WA (en) 2018-12-28
KR20190024876A (ko) 2019-03-08
US20190144455A1 (en) 2019-05-16
AU2017260305A1 (en) 2018-12-13
PH12018502337A1 (en) 2019-07-08
PL3452475T3 (pl) 2020-08-24
EP3452475A1 (en) 2019-03-13
WO2017191304A1 (en) 2017-11-09
TW201808955A (zh) 2018-03-16
EP3452475B1 (en) 2020-02-26
HRP20200668T1 (hr) 2020-10-16
US10590140B2 (en) 2020-03-17
PT3452475T (pt) 2020-05-05
ZA201807653B (en) 2019-06-26
AR108387A1 (es) 2018-08-15
CN109526220B (zh) 2021-12-21
MX2018013471A (es) 2019-06-06
JP2019515039A (ja) 2019-06-06
HUE051829T2 (hu) 2021-03-29
RS60528B1 (sr) 2020-08-31
SMT202000365T1 (it) 2020-09-10
LT3452475T (lt) 2020-05-11
DK3452475T3 (da) 2020-04-27
SI3452475T1 (sl) 2020-07-31
TN2018000372A1 (en) 2020-06-15
MY196791A (en) 2023-05-03
UA123789C2 (uk) 2021-06-02
RU2018141084A (ru) 2020-06-08
IL262825A (en) 2018-12-31
ES2789676T3 (es) 2020-10-26

Similar Documents

Publication Publication Date Title
CO2018012002A2 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CO2019000207A2 (es) Compuestos bicíclicos como plaguicidas
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
DOP2017000298A (es) Reguladores de nrf2
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
DOP2019000290A (es) Inhibidores de quinasa y usos de los mismos
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CO2019006687A2 (es) Polimorfos
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CO2019006673A2 (es) Polimorfos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
UY36702A (es) Piridinas sustituidas y métodos de uso
UY36651A (es) Compuestos antiestrogénicos
NI202000042A (es) Polimorfos
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2